ABOUT US

ABOUT US

Accelerating drug development with synthetic biology and next-generation sequencing

 

We are a team of synthetic biologists and next-generation sequencing experts focused on disrupting the way that pharmaceutical companies discover, optimize, and characterize drugs.

 

Central to our vision is AlphaSeq, the leading technology for quantitative, multi-target characterization of biologics and small molecules that modulate protein interactions.

‚Äč

A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology. 

ABOUT US

Management Team

BEST_linkedin.jpg

David co-invented AlphaSeq while working on his PhD in Bioengineering at the University of Washington with scientific advisors David Baker and Eric Klavins. He is an expert in developing and optimizing high-impact technologies by combining genetic engineering and next-generation sequencing.

UNADJUSTEDNONRAW_thumb_1f80.jpg

Randolph received his PhD in Bioengineering from the University of Washington. Before UW, he was a Process Development Engineer at Illumina where he was responsible for improving quality control efficiency and translating products into manufacturing. Since then, he has expanded his expertise into synthetic biology and computer science.

Advisors

Dr. Eric Klavins, PhD

SCIENTIFIC ADVISOR  

Professor, UW Electrical Engineering

Director, UW Center for Synthetic Biology

Director, UW BIOFAB

Dr. David Baker, PhD

SCIENTIFIC ADVISOR

Professor, UW Biochemistry & HHMI

Director, UW Institute for Protein Design

Member, NAS & AAS

Dr. Lance Stewart, PhD, MBA

BUSINESS ADVISOR  

CSOO, UW Institute for Protein Design

Co-founder, Beryllium Discovery & Northwest NeuroNeighborhood

Brian Glaister

BUSINESS ADVISOR 

Founder & CEO, Octavia & Cadence Biomedical

Advisor, Jones & Foster Accelerator Program

Supported by:

Join us as we remove the guesswork from drug development

Copyright  ©  2019  A-Alpha Bio, Inc. - All Rights Reserved